NY-ESO-1-specifc T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer a dual-targeted cancer therapeutic route
期刊杂志:Cancer Cell International
影响因子:5.8
客户单位:中国科学院广州生物医药与健康研究院
助力服务:外周血单个核细胞(PBMC)分离制备服务